NCT02404558View on ClinicalTrials.gov

Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Rheumatoid Arthritis
Interventions
DRUG

sarilumab SAR153191 (REGN88)

Pharmaceutical form:solution Route of administration: Subcutaneous injection

DRUG

tocilizumab

Pharmaceutical form:solution Route of administration: Subcutaneous injection

Trial Locations (3)

Unknown

Investigational Site Number 392001, Sendai

Investigational Site Number 392002, Sendai

Investigational Site Number 392003, Sendai

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY